Top

Clinical and Translational Oncology

Published in:

01-07-2019 | Research Article

The clinical significance of the alternative Wilms tumor gene overexpression–hypermethylation signature in acute myeloid leukemia

Authors: M. El Bordiny, A. Al-Ghandour, R. A. Abo Elwafa, O. Fayed

Published in: Clinical and Translational Oncology | Issue 7/2019

Abstract

Background

Wilms tumor 1 (WT1) gene is overexpressed in numerous cancers, including acute myeloid leukemia (AML). The alternative WT1 gene (AWT1) is generated from alternative transcription start site in the WT1 first intron and encodes an N-terminal-truncated protein lacking the repressor domain. Although WT1 overexpression is a common feature in AML, the expression levels of the AWT1 and its underlying epigenetic alterations, as well as their clinical relevance in AML remain unknown.

Methods

Quantitative assessment of AWT1 gene transcripts was performed using real-time polymerase chain reaction (PCR). Bisulfite PCR followed by pyrosequencing was done to determine the methylation status of the AWT1 promoter. The bone marrow samples were collected at diagnosis and after completion of induction chemotherapy from 80 newly diagnosed AML patients. Forty non-malignant BM samples were recruited as controls.

Results

The AWT1 was significantly overexpressed in AML patients. Robust hypermethylation of the AWT1 promoter was found to be a highly specific and sensitive marker for AML (p < 0.001). Significant positive correlations between the AWT1 expression and methylation levels with BM blast counts at both initial diagnosis and after induction therapy were observed (p < 0.001). AWT1 overexpression at the initial diagnosis of AML was found to be an independent negative factor for complete remission response after induction therapy (p = 0.014).

Conclusion

The AWT1 gene overexpression–hypermethylation signature is a characteristic marker that positively correlates with the leukemic burden in AML. AWT1 overexpression at AML diagnosis is an independent negative predictor for CR after induction chemotherapy.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196.CrossRefPubMedPubMedCentral

Parenti R, Perris R, Vecchio GM, Salvatorelli L, Torrisi A, Gravina L, et al. Immunohistochemical expression of Wilms’ tumor protein (WT1) in developing human epithelial and mesenchymal tissues. Acta Histochem. 2013;115(1):70–5. https://doi.org/10.1016/j.acthis.2012.04.006.CrossRefPubMed

Parenti R, Salvatorelli L, Musumeci G, Parenti C, Giorlandino A, Motta F, et al. Wilms’ tumor 1 (WT1) protein expression in human developing tissues. Acta Histochem. 2015;117(4–5):386–96. https://doi.org/10.1016/j.acthis.2015.03.009.CrossRefPubMed

Maugeri G, D’Amico AG, Rasa DM, Reitano R, Saccone S, Federico C, et al. Expression profile of Wilms Tumor 1 (WT1) isoforms in undifferentiated and all-trans retinoic acid differentiated neuroblastoma cells. Genes Cancer. 2016;7(1–2):47–58. https://doi.org/10.18632/genesandcancer.94.PubMedCrossRefPubMedCentral

Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem. 2006;281(38):28122–30. https://doi.org/10.1074/jbc.m512391200.CrossRefPubMed

Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms’ tumours. Hum Mol Genet. 2004;13(4):405–15. https://doi.org/10.1093/hmg/ddh038.CrossRefPubMed

Marjanovic I, Karan-Djurasevic T, Ugrin M, Virijevic M, Vidovic A, Tomin D, et al. Use of Wilms tumor 1 gene expression as a reliable marker for prognosis and minimal residual disease monitoring in acute myeloid leukemia with normal karyotype patients. Clin Lymphoma Myeloma Leuk. 2017;17(5):312–9. https://doi.org/10.1016/j.clml.2016.12.006.CrossRefPubMed

Allahyari A, Sadeghi M, Ayatollahi H, Yazdi HN, Tavakol M. Frequency of FLT3 (ITD, D835) Gene mutations in acute myelogenous leukemia: a report from Northeastern Iran. Asian Pac J Cancer Prev. 2016;17(9):4319–22.PubMed

Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, et al. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008;10(3):212–6. https://doi.org/10.2353/jmoldx.2008.070166.CrossRefPubMedPubMedCentral

10.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMed

11.

Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev. 2009;35(2):97–120. https://doi.org/10.1016/j.ctrv.2008.09.001.CrossRefPubMed

12.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

13.

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the acute leukemia french association. Cancer. 2009;115(16):3719–27. https://doi.org/10.1002/cncr.24442.CrossRefPubMed

14.

Ishikawa Y, Kiyoi H, Naoe T. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. Leuk Res. 2011;35(5):685–8. https://doi.org/10.1016/j.leukres.2011.01.002.CrossRefPubMed

15.

Lopotova T, Nadvornikova S, Zackova M, Polak J, Schwarz J, Klamova H, et al. N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia. Leuk Res. 2012;36(4):e81–3. https://doi.org/10.1016/j.leukres.2011.12.008.CrossRefPubMed

16.

Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17(7):1301–12. https://doi.org/10.1038/sj.leu.2402988.CrossRefPubMed

17.

Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, et al. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol. 2014;7:4. https://doi.org/10.1186/1756-8722-7-4.CrossRefPubMedPubMedCentral

18.

Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, et al. GATA-1 and GATA-2 binding to 3′ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia. 2009;23(7):1270–7. https://doi.org/10.1038/leu.2009.13.CrossRefPubMed

19.

Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin Cancer Biol. 2002;12(5):347–57.CrossRefPubMed

20.

Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16(R1):R50–9. https://doi.org/10.1093/hmg/ddm018.CrossRefPubMed

21.

Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer. 2008;98(12):1881–5. https://doi.org/10.1038/sj.bjc.6604374.CrossRefPubMedPubMedCentral

22.

Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al. Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 2001;61(3):921–5.PubMed

Title: The clinical significance of the alternative Wilms tumor gene overexpression–hypermethylation signature in acute myeloid leukemia
Authors: M. El Bordiny
A. Al-Ghandour
R. A. Abo Elwafa
O. Fayed
Publication date: 01-07-2019
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 7/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1998-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2019

CEP55 promotes epithelial–mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway

High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients

Integrative diagnosis of cancer by combining CTCs and associated peripheral blood cells in liquid biopsy

Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database

Ovarian metastasis from breast cancer: a comprehensive review

Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer